Known for his contributions to the fundamental understanding of the tau protein, Skip Binder leaves his mark on the Alzheimer's field.
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
Stacked together, amyloid subunits absorb more light than they do as monomers. Are there implications for fibril detection?
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Researchers can vote for the winner of this year’s Geoffrey Beene NeuroDiscovery Challenge.
A repeat expansion that causes neurodegenerative disease is transcribed both forward and backward, producing sense and antisense RNAs and multiple polypeptides.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
Screens of yeast and human-derived neurons uncover reasons for α-synuclein toxicity and potential ways to prevent it.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.